EUCTR2013-003467-60-NL进行中（未招募）1 期
A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients with Knee Osteoarthritis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject must have radiographic evidence of knee osteoarthritis in the medial compartment of the index knee with Kellgren-Lawrence Grade 2 or 3 (with minimum 2 mm joint space width) during Screening as evaluated by a qualified central imaging reader. Prior radiographs taken no more than 3 months before Study Day 1 with Synaflexer™ can be
- •submitted for centralized eligibility reading.
- •2. Subject must have either constant or intermittent index knee pain at least 14 days (regardless the intensity)over the past 30 days at the initial screening visit. The intensity of index knee pain is between 4 and 8 , inclusive, at the initial Screening Visit and Study Day 1 (as recorded on question 1 of the Index Knee Pain Intensity Questionnaire.
- •3.Subject has one or more clinical signs and symptoms of active inflammation in the index knee as defined by (but not limited to) localized pain, joint stiffness, swelling and effusion during Screening and Study Day 1.
- •4.Presence of synovitis in the index knee confirmed by ultrasound or MRI during Screening.
- •5.Subject discontinued analgesics, non-steroidal anti-inflammatory drugs (NSAIDS) and nutraceuticals (e.g., glucosamine, chondroitin sulfate, shark cartilage, diacerein, soy extract). The washout period will be at least 5 half-lives of the longest acting analgesic used, or 48 hours, whichever is longer prior to first dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •1.History of major allergic reaction or significant sensitivity to any constituents of the study drug, history of anaphylactic reaction to any agent (e.g., food products or bee stings) or history of a major reaction to any Immunoglobulin G (IgG-)containing product.
- •2.Significant trauma or surgery to the index knee within the last year or arthroscopy of the index knee within 6 months of Screening.
- •3.Kellgren-Lawrence Grade 1 or 4 in the index knee.
- •4.Severe knee malalignment, either greater than 4.0° in varus; or greater than 8.0° in valgus angulation in the index knee.
- •5.Diagnosis of one or more of the following:
- •a.Inflammatory arthritis such as rheumatoid arthritis, autoimmune disorder, seronegative spondyloarthropathy, gout, or pseudogout (defined as acute episodic attacks of swollen , painful joints in a subject with X-Ray chondrocalcinosis or CPPD crystals);
- •b.Other chronic painful syndromes (such as Paget's disease and fibromyalgia) and clinically significant non-articular musculoskeletal pain that could interfere with assessment of pain at the index knee.
- •6. History or evidence of active tuberculosis (TB)
- •7. Any uncontrolled medical illness or unstable treatment ot therapy.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients with Knee OsteoarthritisAdult male and female patients with mild to moderate, symptomatic, radiographic and inflammatory osteoarthritis of the kneeMedDRA version: 18.0Level: PTClassification code 10031161Term: OsteoarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-003467-60-GBAbbVie Deutschland GmbH & Co. KG320
进行中（未招募）
1 期
A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients with Knee OsteoarthritisEUCTR2013-003467-60-ESAbbVie Deutschland GmbH & Co. KG320
进行中（未招募）
1 期
A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients with Knee OsteoarthritisEUCTR2013-003467-60-ITAbbVie Deutschland GmbH & Co. KG320
进行中（未招募）
1 期
A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients with Knee OsteoarthritisAdult male and female patients with mild to moderate, symptomatic, radiographic and inflammatory osteoarthritis of the kneeMedDRA version: 18.0Level: PTClassification code 10031161Term: OsteoarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-003467-60-DKAbbVie Deutschland GmbH & Co. KG320
已完成
2 期
A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients with Knee Osteoarthritisostheoarthritispain10023213NL-OMON41808AbbVie B.V.17